AI-assisted drug R&D. Data from clinical and scientific literature, powered by machine learning—for drug design, evaluation, and innovation.
AI 辅助药物研发。基于临床与科学文献数据，结合机器学习，助力药物设计、评估与创新。
InSynBio focuses on AI-assisted drug R&D. We leverage clinical and scientific literature data, combined with machine learning, to deliver AI-driven drug design and evaluation. Our approach integrates computational and experimental workflows (dry-wet combined), supporting clinical translation and drug innovation.
InSynBio 专注 AI 辅助药物研发。我们基于临床与科学文献数据，结合机器学习，提供 AI 驱动的药物设计与评估。采用干湿结合方式，助力临床转化与药物创新。
Long-term vision: Harness established therapeutics for AI-driven innovation and design, as well as de novo drug design.
长远目标：利用现有药物进行 AI 驱动的创新与设计，以及从头设计新药。
In silico assessment, design, and development for biotherapeutics.
提供生物治疗药物的 in silico 评估、设计与开发。
Sequence analysis, developability, immunogenicity, structure, humanization, affinity maturation.
序列分析、可开发性、免疫原性、结构、人源化、亲和力成熟。
Learn more →了解更多 →CAR construct design and optimization.
CAR 构建设计与优化。
BsAb format selection and sequence design.
BsAb 格式选择与序列设计。
Transparent, risk-sharing process.
透明、风险共担的合作流程。
Technical consultation, drug evaluation, and CRO/Biotech collaboration.
技术咨询、药物评估，以及 CRO / Biotech 合作。
We typically respond within 1–2 business days.
我们通常在 1–2 个工作日内回复。
Share your sequences and project details. We will review and get back to you.
提供您的序列与项目详情，我们将审核并回复。
Open inquiry form打开咨询表单